Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

5ab66d03-c324-4ec2-b3bb-7970c121a7f5

—

7ea0f519-5db0-53e8-a73d-95e9ff245d26

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.500
  • G2M_CHECKPOINT+0.400
  • PROTEIN_SECRETION+0.400
  • DNA_REPAIR+0.300
  • MITOTIC_SPINDLE+0.300
  • UNFOLDED_PROTEIN_RESPONSE+0.300
  • MTORC1_SIGNALING+0.200
  • MYC_TARGETS_V1+0.200
  • MYC_TARGETS_V2+0.200
  • OXIDATIVE_PHOSPHORYLATION+0.200

Top 10 suppressed

  • ALLOGRAFT_REJECTION-0.500
  • INTERFERON_ALPHA_RESPONSE-0.500
  • INTERFERON_GAMMA_RESPONSE-0.500
  • IL6_JAK_STAT3_SIGNALING-0.400
  • INFLAMMATORY_RESPONSE-0.400
  • COMPLEMENT-0.300
  • ESTROGEN_RESPONSE_LATE-0.300
  • IL2_STAT5_SIGNALING-0.300
  • KRAS_SIGNALING_DN-0.300
  • KRAS_SIGNALING_UP-0.300

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1SAMN03290931
melanoma-umap@29
——0.889
2MDT-AP-1353
medullo-epn-umap@date-based
MedMedulloblastoma0.886
3BS_G23JJAZY
brain-umap@2
Supratentorial Ependymoma—0.879
4MDT-AP-0714
medullo-epn-umap@date-based
MedMedulloblastoma0.879
5BS_WVW3W6ZB
brain-umap@2
ATRT—0.876
6TCGA-C8-A1HN-01A-11R-A137-07
breast-umap@18
—B0.875
7MDT-AP-2085
medullo-epn-umap@date-based
MedMedulloblastoma0.875
8c6e243ee-b2d9-408e-ac05-ccbcffa805ab
melanoma-umap@29
——0.872
9MDT-AP-0155
medullo-epn-umap@date-based
MedMedulloblastoma0.871
10236350e9-8964-42ae-8880-d2f2281ff993
melanoma-umap@29
——0.870

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 19 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.500Inavolisib— uncovered
G2M_CHECKPOINT0.400Inavolisib— uncovered
PROTEIN_SECRETION0.400Remibrutinib— uncovered
DNA_REPAIR0.300Idelalisib— uncovered
MITOTIC_SPINDLE0.300Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.300Idelalisib— uncovered
MTORC1_SIGNALING0.200Inavolisib— uncovered
MYC_TARGETS_V10.200Inavolisib— uncovered
MYC_TARGETS_V20.200Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.200Remibrutinib— uncovered
TGF_BETA_SIGNALING0.200Inavolisib— uncovered
ADIPOGENESIS0.100Inavolisib— uncovered
GLYCOLYSIS0.100Inavolisib— uncovered
P53_PATHWAY0.100Idelalisib— uncovered
PEROXISOME0.100Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.100Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.100Inavolisib— uncovered
SPERMATOGENESIS0.100Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.100Inavolisib— uncovered